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Abstract: BACKGROUND: Careful selection of malignant pleural mesothelioma (MPM) patients for
curative treatment is of highest importance, as the multimodal treatment regimen is challenging for
patients and harbors a high risk of substantial toxicity. Radiomics-a quantitative method for image
analysis-has shown its prognostic ability in different tumor entities and could therefore play an important
role in optimizing patient selection for radical cancer treatment. So far, radiomics as a prognostic tool in
MPM was not investigated. MATERIALS AND METHODS: This study is based on 72 MPM patients
treated with surgery in a curative intent at our institution between 2009 and 2017. Pre-treatment
Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for radiomics outcome modeling.
After extraction of 1404 CT and 1410 FDG PET features from each image, a preselection by principal
component analysis was performed to include only robust, non-redundant features for the cox regression
to predict the progression-free survival (PFS) and the overall survival (OS). Results were validated on
a separate cohort. Additionally, SUVmax and SUVmean, and volume were tested for their prognostic
ability for PFS and OS. RESULTS: For the PFS a concordance index (c-index) of 0.67 (95% CI 0.52-0.82)
and 0.66 (95% CI 0.57-0.78) for the training cohort (n = 36) and internal validation cohort (n = 36),
respectively, were obtained for the PET radiomics model. The PFS advantage of the low-risk group
translated also into an OS advantage. On CT images, no radiomics model could be trained. SUV max
and SUV mean were also not prognostic in terms of PFS and OS. CONCLUSION: We were able to build
a successful FDG PET radiomics model for the prediction of PFS in MPM. Radiomics could serve as a
tool to aid clinical decision support systems for treatment of MPM in future.
DOI: https://doi.org/10.1186/s13550-020-00669-3






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Pavic, M; Bogowicz, M; Kraft, J; Vuong, D; Mayinger, M; Kroeze, S G C; Friess, M; Frauenfelder, T;
Andratschke, N; Huellner, M; Weder, W; Guckenberger, M; Tanadini-Lang, S; Opitz, I (2020). FDG




ORIGINAL RESEARCH Open Access
FDG PET versus CT radiomics to predict
outcome in malignant pleural
mesothelioma patients
M. Pavic1* , M. Bogowicz1, J. Kraft1, D. Vuong1, M. Mayinger1, S. G. C. Kroeze1, M. Friess2, T. Frauenfelder3,
N. Andratschke1, M. Huellner4, W. Weder2, M. Guckenberger1, S. Tanadini-Lang1 and I. Opitz2
Abstract
Background: Careful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of
highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of
substantial toxicity. Radiomics—a quantitative method for image analysis—has shown its prognostic ability in
different tumor entities and could therefore play an important role in optimizing patient selection for radical cancer
treatment. So far, radiomics as a prognostic tool in MPM was not investigated.
Materials and methods: This study is based on 72 MPM patients treated with surgery in a curative intent at our
institution between 2009 and 2017. Pre-treatment Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for
radiomics outcome modeling. After extraction of 1404 CT and 1410 FDG PET features from each image, a preselection by
principal component analysis was performed to include only robust, non-redundant features for the cox regression to
predict the progression-free survival (PFS) and the overall survival (OS). Results were validated on a separate cohort.
Additionally, SUVmax and SUVmean, and volume were tested for their prognostic ability for PFS and OS.
Results: For the PFS a concordance index (c-index) of 0.67 (95% CI 0.52–0.82) and 0.66 (95% CI 0.57–0.78) for the training
cohort (n = 36) and internal validation cohort (n = 36), respectively, were obtained for the PET radiomics model. The PFS
advantage of the low-risk group translated also into an OS advantage. On CT images, no radiomics model could be
trained. SUV max and SUV mean were also not prognostic in terms of PFS and OS.
Conclusion: We were able to build a successful FDG PET radiomics model for the prediction of PFS in MPM. Radiomics
could serve as a tool to aid clinical decision support systems for treatment of MPM in future.
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Background
Malignant pleural mesothelioma (MPM) is an aggressive
thoracic malignancy with a dismal prognosis. The tumor
originates from cells of the visceral or parietal pleural
and is linked to asbestos exposure with a median latency
of 44.6 years [1]. Due to the latency between exposure
and onset of mesothelioma and the ongoing use of
asbestos in parts of the world, the incidence is expected
to rise continuously in the next years, necessitating im-
provements in management of these patients. Life ex-
pectancy is still poor today, with a median overall
survival of approximately 12 months [2]. Multimodal
treatment strategy is associated with a prolonged median
survival of up to 29 months, but also harbors the risk of
increased toxicity [3, 4]. Adjuvant radiation therapy after
chemotherapy and radical surgery was investigated in a
multicenter phase II trial and did not show a benefit for
locoregional relapse-free survival and thus cannot be
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considered as a standard adjuvant treatment for MPM
patients [5]. To date, most centers offer multimodal
treatment consisting of (neo-)adjuvant chemotherapy
in conjunction with maximal surgical cytoreduction
[6]. However, only a minor subset of all newly diag-
nosed patients is considered to be eligible for such
radical surgery. The vast majority of patients receive
palliative systemic therapy. Careful selection of appro-
priate candidates for a curatively intended and poten-
tially toxic multimodal treatment is of highest
importance, asking for prognostic factors and scores.
There are some known clinical prognostic factors,
such as the performance status and histology among
others [7], that are incorporated into the EORTC–
prognostic score. Based on this, a discrimination of
pleural mesothelioma patients into a good- and a
poor-prognosis group is possible [8].
Recently, morphological features derived from medical
images were discovered as additional important prog-
nostic factors. Tumor volumetry and maximal pleural
thickness on axial CT slices were prognostic in terms of
median survival [9, 10]. The International Association
for the Study of Lung Cancer (IASLC)/International
Mesothelioma Interest Group (IMIG) database reported
a correlation between the maximal pleural thickness on
axial CT slices and T stage (according TNM 7th edi-
tion), overall stage, nodal stage, and survival [11].
Radiomics is an advanced computational method to
describe tumors in a more comprehensive way than sim-
ple measurements. Shape, intensity, and texture of a
tumor are quantified on medical images through math-
ematical analysis, resulting in hundreds of extracted fea-
tures [12]. By applying mathematically defined filters,
even more information can be extracted from images by,
e.g., enhancing high and low frequency components of
the images, such as edges and reduced noise. Radiomic
signatures were shown to be prognostic for survival and
local tumor control in multiple tumor entities [13].
However, MPM has not been investigated yet using this
approach. The aim of our study was to analyze the prog-
nostic ability of CT-based and Fluorine-18 fluorodeoxy-
glucose (FDG) PET-based radiomics models for the
prediction of progression-free-survival (PFS) and overall




In total, 72 MPM patients were studied retrospectively
out of 123 patients referred for treatment to the Univer-
sity Hospital Zurich between 2009 and 2017. Clinical pa-
rameters and initial pre-therapeutic staging by FDG
PET/CT were available. Confirmation of diagnosis by
histological examination of biopsy specimens was
available in all subjects. All patients underwent curative
treatment consisting of at least aggressive surgery. In-
duction chemotherapy with platinum and pemetrexed,
administered for 3 to 4 cycles, was performed in 60 out
of 72 patients. Curative surgery was performed either by
extrapleural pneumonectomy (EPP) or pleurectomy/de-
cortication (P/D). The training and the validation cohort
consisted of 36 patients each (split by date of treatment).
Median follow-up was 51.9 months (22.4–70.5 months)
and 24.1 months (13.5–39.8 months), overall survival
(OS) was 21.5 months (2.6–74.8 months) and 23.7
months (5.9–39.8 months) and PFS was 11.3 (range 2.6–
51.9 months) and 11.7 (5.0–39.8 months) for training
and validation cohort, respectively. Detailed patients’
characteristics are provided in Table 1.
Image acquisition and definition of volumes
For all patients, pretreatment FDG PET and native CT
scans were available. Blood glucose level was measured
prior to FDG PET/CT. All PET scans were corrected for
decay, attenuation, scatter, dead time, and random. De-
tails on scanning parameters are provided in Table 2. To
reduce variability in imaging acquisition between pa-
tients, non-contrast-enhanced CT scans were used as
some patients did not receive contrast due to various
reasons. Manual delineation of the primary tumors was
performed by four radiation oncologists (with more than
3 years of experience) on co-registered CT and FDG
PET images according to a study-specific protocol: all
FDG PET-positive masses were included as well as FDG
PET-negative but highly suspicious pleural thickenings,
lung nodules, infiltrated pericardium and mediastinal ex-
tension on CT imaging. Pleural effusion and atelectasis
were excluded. Contouring was performed either in
Eclipse (Varian Medical Systems VR, Palo Alto, CA) or
MIM Vista (Version 6.7.9, MIM Software Inc. VR,
Cleveland, OH).
Table 1 Patient characteristics
Training cohort (n = 36) Validation
cohort (n = 36)

























Induction chemotherapy (%) 25 (69) 35 (97)
P/D pleurectomy/decortication, EPP extrapleural pneumonectomy
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Image pre-processing and radiomics analysis
The in-house developed radiomics software Z-rad writ-
ten in Python programing language (version 2.7.6) was
used to analyze the 3D images by extracting shape, in-
tensity, texture, and wavelet features. This software
package was benchmarked in the Image Biomarker
Standardization Initiative [14]. For intensity, texture, and
wavelet analysis, images were resized to cubic voxels of
3.3 mm in CT and 5.5 mm in PET using linear
interpolation. These voxel sizes correspond to the most
common image resolution in CT (sagittal) or PET
(axial). Additionally, Hounsfield units (HU) range − 300
to 200 in CT was applied to limit the analysis to tumor
tissue only. These adapted CT contours were then trans-
ferred to the PET images. To quantify the texture and
wavelet, images were discretized to equally spaced bins
of 5 HU in CT and 0.25 SUV in FDG PET.
In total, 1404 features from CT images and 1410 fea-
tures from FDG PET images were extracted, according
to Pavic et al [15]. All details on definitions and descrip-
tion of analyzed features are provided in that paper and
online on the website giving a detailed overview on the
radiomics software including code and definition of fea-
tures [16]. Six additional features for the FDG PET im-
aging described volumes exhibiting metabolism above
certain threshold of the maximum SUV (metabolic
tumor volume 20%, 30%, 40%, 50%, 60%, 70%). To ac-
count for differences in contouring between the different
observers, only stable features irrespective of differences
in tumor contouring were considered for further ana-
lysis. For CT images, this analysis was done on 11 cases
out of the entire cohort in a previous work and a de-
tailed list of all extracted as well all stable CT features
used for modeling is provided in supplementary material
of the above-mentioned inter-observer delineation vari-
ability study [15]. For FDG PET images, the analysis on
stable features was done prior to feature extraction on
the same 11 MPM cases and following the same proced-
ure as for the CT study. In brief, for each region of inter-
est, the radiomics analysis was performed and
consistency of the three respective results was tested
using the intraclass correlation coefficient (ICC), where-
upon an ICC > 0.8 was accepted as a value to indicate
robustness [17]. The description of procedures is de-
tailed in a publication on CT scans by Pavic et al. [15].
Statistical analysis
Statistical analysis was performed in R (version 3.3.2).
OS and PFS were determined from the date of initial
diagnosis. First, features with more than 20% missing
Table 2 Scanning parameters
Scanning characteristics/parameters Training cohort (= 36) Validation cohort (= 36)
CT scanners Siemens Biograph40 (n = 9)
GE Discovery STE (n = 7)
GE Discovery 690 (n = 15)
GE Discovery VCT (n = 5)
Siemens Biograph40 (n = 16)
Siemens Biograph128 (n = 4)
GE Discovery STE (n = 3)
GE Discovery 690 (n = 3)
GE Discovery VCT (n = 7)
GE Discovery 600 (n = 1)
GE Discovery MI (n = 2)
- Slice thickness (mm) 2.5–4 1.25–3.27
- In-plane resolution (mm) 0.98–1.52 0.98–1.52
- kV 100; 120; 140 100; 120; 140
- mAs 62–402 23–136
- Reconstruction kernel Soft kernel (n = 33)
Sharp kernel (n = 3)
Soft kernel (n = 20)
Sharp kernel (n = 16)
PET scanners Siemens Biograph40 (n = 9)
GE Discovery STE (n = 7)
GE Discovery 690 (n = 15)
GE Discovery VCT (n = 5)
Siemens Biograph40 (n = 15)
Siemens Biograph128 (n = 4)
GE Discovery STE (n = 3)
GE Discovery 690 (n = 4)
GE Discovery VCT (n = 7)
GE Discovery 600 (n = 1)
GE Discovery MI (n = 2)
- Slice thickness (mm) 2.5–4 2–3.27
- In-plane resolution (mm) 2.73–5.47 2.73–5.47
- Administered FDG activity (MBq), median (range) 337.5 (188–417) 316.3 (204.1–408)
- Delay between administration of FDG and scanning (min) 46.1–85.6 49.8–91.1
- Reconstruction algorithm 3D OSEM (n = 18)
3D OSEM with PSF (n = 18)
3D OSEM (n = 24)
3D OSEM with PSF (n = 12)
kV kilovolt, mAs milliampere-second, MBq Mega Becquerel, OSEM ordered subset expectation maximization., PSF point spread function modeling
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values or low variability were excluded from the analysis.
The remaining features were grouped using principal
component analysis, and the Horn method was used for
definition of the optimal number of retained components
[18]. Univariable Cox regression analysis was applied to
determine prognostic value of correlated features. Per
principal component related group, the feature with the
highest Concordance Index (c-index), and corresponding
false discovery rate < 0.25 in the univariable Cox regres-
sion was selected. The prognostic non-redundant features
(one feature per principal component group) were entered
in the multivariate Cox regression analysis with backward
selection of variables using Akaike information criterion.
For the split into risk groups, we used 80th percentile of
the predictions in the training cohort, yielding a threshold
of 0.35. We have chosen the split percentile based on the
most significant result in the training cohort. The model
was validated in the separate cohort of 36 patients. The
risk group stratification was studied with the G-rho test. A
p value below 0.05 was considered significant.
In order to test the added value of a radiomics analysis
over routinely gathered information by PET-CT, that
was already shown to have prognostic value, we calcu-
lated the prognostic power of standard uptake value
(SUV) max and SUV mean and of volume for PFS and
OS [9, 19] (Fig. 1).
Results
Robustness of FDG PET-radiomics
In the cohort of 11 MPM patients, on which the stability
of CT radiomics results according to the inter-observer
delineation variability was tested previously, 780 out of
1410 FDG PET features (55.3%) were stable against vari-
ability in tumor segmentation. The stable features in-
cluded 1 shape (5.6% shape features), 20 intensity (87%
intensity features), 82 texture (59.9% texture features),
and 677 wavelet features (55% wavelet features). Add-
itional file 1: Tables 1, 2, 3, and 4 provide the full list of
stable features.
CT radiomics model
For the PFS, dimensionality reduction by PCA derived
five groups of correlated features in the training cohort.
Only one group contained features with a good discrim-
inative power. The final model consisted of one radiomic
feature: “LHH GLRLM long run high grey level em-
phasis” (a wavelet feature).
For the OS, dimensionality reduction by PCA derived
five groups of correlated features, that all contained fea-
tures with a good discriminative power. After backward
selection, the final model consisted of three radiomic
features: “GLSZM grey level non-uniformity” (a texture
feature),”HLH GLCM homogeneity” (a wavelet feature),
and “LHH intensity range” (a wavelet feature). However,
for both PFS and OS, the model could not be success-
fully validated (see Table 3). Thus, no CT radiomics
model with a good prognostic ability could be generated.
FDG PET radiomics model
For the PFS, dimensionality reduction by PCA resulted
in three groups of correlated FDG PET features in the
training cohort. All three groups contained features with
a good discriminative power. After backward selection,
the final model consisted of three radiomic features:
“HLH intensity range,” “HLH GLSZM high grey level
zone emphasis,” and “HLH GLCM maximal correlation
coefficient.” All three features represent wavelet features.
The model performance was first estimated in 5-fold
cross validation in the training cohort with a mean c-
index of 0.67 (95% CI 0.52–0.82). The performance of
the model for the validation cohort showed a good prog-
nostic power with a c-index of 0.66 (95% CI 0.57–0.78).
The model splits the patients into groups with signifi-
cantly different PFS in the training (11 vs. 7 months, p
0.05) as well as in the validation (12.5 vs. 9 months, p <
0.001) cohort (see Fig. 2). Our PFS PET radiomics prog-
nostic model showed also good discrimination for OS
with c-index = 0.66 (95% CI 0.52–0.80). Details for the
Cox model are provided in Additional file 3 in supple-
mentary material.
Fig. 1 Overview of radiomics workflow
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For the OS, dimensionality reduction by PCA resulted
in three groups of correlated FDG PET features in the
training cohort. All three groups contained features with a
good discriminative power. After backward selection, the
final model consisted of two radiomic features: “LHH
GLSZM small zone high grey level emphasis” and “LLL
GLCM information measures of correlation 2”—both
representing wavelet features. The model performance
first estimated in 5-fold cross validation in the training co-
hort showed a mean c-index of 0.72 (95% CI 0.62–0.84).
The performance of the model for the validation cohort
showed a poor prognostic power with a c-index of 0.47
(95% CI 0.36–0.62).
SUV and volume results
For the PFS and OS, the performance of SUVmax was c-
index = 0.55 (0.44–0.60) and c-index = 0.54 (0.42–0.68),
respectively. Performance of SUVmean for PFS was c-
index = 0.52 (0.40–0.66) and for OS c-index = 0.48 (0.39–
0.61). Thus, on the training cohort, no prognostic model
could have been built based on SUVmax and SUVmean.
The volume-based model showed no prognostic
performance for PFS with a c-index of 0.60 (0.49–
0.73) and a c-index of 0.57 (0.48–0.67) for the train-
ing and validation cohort, respectively. Yet, for the
OS, the model was prognostic with a c-index of 0.62
(0.52–0.72) and a c-index of 0.63 (0.50–0.75) for the
training and validation cohort, respectively (see Add-
itional file 2: Figure 1). See Table 3 for an overview
of results.
Discussion
We were able to train a radiomics model on pre-
treatment FDG PET images being predictive for the PFS.
Table 3 Overview of modeling results
Performance of model PFS OS



































PFS progression-free-survival, OS overall survival
Fig. 2 Cox regression results for FDG PET radiomics model for PFS
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The significant but in terms of absolute numbers moder-
ate PFS advantage translated also into an OS difference
when applying the radiomics model developed on the
PFS to test for the OS differentiation. On the contrary, a
simple model based on SUVmax or SUVmean had no
prognostic power for PFS nor OS. Volume was prognos-
tic for the OS but showed lower c-index than the FDG
PET radiomics-based PFS model.
The ability of radiomics on CT and MRI images to
support the diagnostic process of differentiation between
benign and malignant pleural lesions has recently been
proposed with an AUC of 0.92 for the CT model and
AUC of 0.87 for the MR model [20]. However, to the
best of our knowledge, no radiomics model for outcome
prediction in pleural mesothelioma patients has been re-
ported yet. The Multimodality Prognostic Score (MMPS;
range 0–4) was generated to identify patients which may
benefit most from an aggressive multimodal treatment
[10]. Using the following prognostic factors, the MMPS
could distinguish patients with different prognosis in
terms of OS: tumor volume pre-chemotherapy (pre-
CTX) > 500 ml, CRP pre-CTX > 30 mg/l, non-
epithelioid histology in pre-CTX biopsy, and progressive
disease according to modified RECIST criteria [21]. Pa-
tients with a MMPS of ≥ 3 did experience a significantly
shorter OS. Our cohort consisted of patients all being
eligible for aggressive surgery, and we had no patient
with an MMPS of ≥ 3 included—therefore, a comparison
of the radiomics model with the MMPS score is not pos-
sible. The MMPS allows selection of patients for referral
to surgery after induction chemotherapy. Our radiomics
model was developed on medical images acquired before
any treatment was initiated and could therefore in future
contribute to a prediction model and decision-support
system for individualized treatment strategy before initi-
ation of induction chemotherapy. A notable advantage
of prediction models based on images is that these med-
ical images are routinely acquired for diagnostic pur-
poses—the ASCO guidelines recommend an FDG PET/
CT as staging method for all MPM patients considered
candidates for definitive surgical resection [6]—and
therefore are available for all patients without the need
for an additional procedure.
The final FDG PET radiomics model for prediction of
PFS comprised three wavelet features, “HLH intensity
range,” “HLH GLSZM high grey level zone emphasis,”
and “HLH GLCM maximal correlation coefficient.” All
the features in the final model were extracted from the
HLH wavelet map [22]. The HLH wavelet filtering
emphasizes the SUV heterogeneity in 2 out of 3 dimen-
sions. The maximal correlation coefficient is a correl-
ation measure and high grey level zone emphasis takes
high values in the images with larger patches of high in-
tensity. For both of those features, higher values were
associated with worse prognosis. The intensity range
corresponds to the range of wavelet coefficients in the
ROI. In contrary to other features, the lower intensity
range was associated with worse prognosis.
A strength of our study is the implementation of radio-
mics for MPM. This tumor is characterized by a very het-
erogeneous shape and diffuse growth along the pleura and
frequent infiltration of thoracic structures. Therefore, this
tumor is difficult for contouring. A prerequisite for imple-
mentation of a radiomics model as a decision-making tool
into clinical routine is robustness of every individual step in
the process—one important step in the radiomics workflow
is segmentation of the region of interest. Inter-observer
variability in contouring of the tumor was investigated for
several sites and can be substantial [23, 24]. To account for
this uncertainty, we used only features in our model, which
are robust irrespective of variations in contouring [15]. In
total, 505 features were used for CT and 780 for FDG PET
radiomics in the current analysis. Thus, a higher proportion
of FDG PET features was stable compared to CT features.
The potential reason for the higher percentage of stable
features lies within the imaging modality itself: high-FDG
uptake in PET images is quite apparent and contouring
variability is expected to occur mainly in rim regions where
low-FDG uptake or blurring is present. This rim region
represents only a minor sub-volume compared to the
whole FDG uptake area and therefore, uncertainties in this
region do not lead to a high variability of radiomics results.
Another possible factor is the bigger voxel size of 5.5 mm
in FDG PET compared to 3.3 mm in CT images.
As already stated, various factors can influence image
quality and therefore have an impact on the results of a
radiomics model on CT as well as on FDG PET images
[25–31]. Acquisition of FDG PET/CT was done on dif-
ferent machines with different parameter settings, which
can affect the robustness of radiomic features [32]. Un-
fortunately, a small size of subcohorts with homogenous
acquisition and reconstruction protocols prevented us
from studying this effect in more detail or to apply cor-
rection methods, such as ComBat [33]. However, our
dataset represent the real-life data heterogeneity. Retro-
spective nature of data collection together with rapid de-
velopment of detector technology and reconstruction
methods makes collection of large and homogenous
datasets difficult. Therefore, we think that the recently
introduced, specialized PET radiomics phantoms depict-
ing heterogeneity of PET tracer uptake are key tools for
robustness studies [32]. One further limitation of this
study is the low patient number analyzed. In total, 505
CT features and 780 FDG PET features were analyzed
for 36 patients in the training cohort. This leads to the
risk of overfitting because we have little data for the
number of analyzed variables [34]. Furthermore, we only
used a multivariate logistic regression to assess the
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relation of radiomics results with patient outcome. As
the prediction of PFS in MPM patients is a complex task
with possible need for more predictor variables, a more
complex model would eventually perform better in
terms of outcome prediction. However, with our limited
number of subjects, such an analysis was not possible
and would require a much larger cohort—potentially re-
quiring a multi-institutional project.
Conclusions
We could show the prognostic potential of a FDG PET-
based radiomics model for PFS in MPM patients on pre-
treatment images. No CT-based model with sufficient
discriminative power could be built. Radiomics could
serve as a tool to aid decision support systems for treat-
ment of patients with MPM—a malignancy whose cura-
tively intended multimodal treatment can be challenging
for patients, therefore, asking for a careful selection of
appropriate candidates. However, further analysis with
inclusion of more data in a multi-centric setting is rec-
ommended to validate the model.
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